TY - JOUR
T1 - New Directions in Pediatric Asthma
AU - Bacharier, Leonard B.
AU - Guilbert, Theresa W.
N1 - Funding Information:
Disclosure Statement: Dr L.B. Bacharier reports grants from NIH ; consultancy and lecture fees from GlaxoSmithKline, Genentech/Novartis, Teva, AstraZeneca, Sanofi/Regeneron, and Boehringer Ingelheim; has received lecture fees from and is on the scientific advisory board for Merck; is on the DBV Technologies data safety monitoring board; has received honoraria for Continuing Medical Education (CME) program development from WebMD/Medscape; is on the advisory boards for Vectura and Circassia; and has received research support from Vectura and Sanofi . T.W. Guilbert reports grants from NIH and Sanofi/ Regeneron ; personal fees from Teva, GSK, Merck, Regeneron Pharmaceuticals, Novartis/Regeneron, Sanofi/Regeneron, Aviragen, and GSK/Regneron; has consulted for American Board of Pediatrics Pediatric Pulmonary Subboard; and has royalities from UpToDate.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/5
Y1 - 2019/5
N2 - Childhood asthma affects many children placing them at significant risk for health care utilization and school absences. Several new developments relevant to the field of pediatric asthma have occurred over the last 5 years; yet, there is much more to learn. It is poorly understood how to prevent the disease, optimally address environmental challenges, or effectively manage poor adherence. Moreover, it is not clear how to customize therapy by asthma phenotype, age group, high risk groups, or severity of disease. Highlights of advances in pediatric asthma are reviewed and multiple essential areas for further exploration and research are discussed.
AB - Childhood asthma affects many children placing them at significant risk for health care utilization and school absences. Several new developments relevant to the field of pediatric asthma have occurred over the last 5 years; yet, there is much more to learn. It is poorly understood how to prevent the disease, optimally address environmental challenges, or effectively manage poor adherence. Moreover, it is not clear how to customize therapy by asthma phenotype, age group, high risk groups, or severity of disease. Highlights of advances in pediatric asthma are reviewed and multiple essential areas for further exploration and research are discussed.
KW - Adherence
KW - Adolescent
KW - Antibacterial agents
KW - Asthma
KW - Biologics
KW - Environmental exposures
KW - Inner-city
KW - Lung function
UR - http://www.scopus.com/inward/record.url?scp=85063739050&partnerID=8YFLogxK
U2 - 10.1016/j.iac.2018.12.012
DO - 10.1016/j.iac.2018.12.012
M3 - Review article
C2 - 30954177
AN - SCOPUS:85063739050
SN - 0889-8561
VL - 39
SP - 283
EP - 295
JO - Immunology and Allergy Clinics of North America
JF - Immunology and Allergy Clinics of North America
IS - 2
ER -